P-141PanCO: An open-label, single-arm pilot study of Oncosil ™ in patients with unresectable locally advanced pancreatic adenocarcinoma in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies

Introduction: Locally advanced pancreatic cancer (LAPC) is associated with a poor prognosis. Current standard treatment is limited to chemotherapy or chemo-radiotherapy. Novel treatment approaches are crucial in attempting to combat this unmet medical need. Phosphorus-32 (P-32) Microparticles is a brachytherapy device that implants a predetermined dose of the beta radiation emitting isotope (P-32) directly into pancreatic tumours via endoscopic ultrasound (EUS) guidance. The presented data are early results from an ongoing international, multi-institutional, single-arm pilot study. The study objective is to determine the safety and efficacy of P-32 Microparticles in a patient population undergoing standard chemotherapy for unresectable LAPC.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research